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Abstract
Background: Prostate cancer (PCa) has one of the highest heritability of all major cancers, where the genetic
contribution has been documented, and knowledge about the molecular genetics of the disease is increasing.
However, the extent and aspects to which genetic variants explain PCa heritability in Africa are limited.
Main body: In this review, we summarize studies that highlight how identified genetic variants explain differences
in PCa incidence and presentation across ethnic groups. We also present the knowledge gaps in PCa genetics in
Africa and why Africa represents an untapped potential ground for genetic studies on PCa. A significant number of
genome-wide association studies, linkage, and fine-mapping analyses have been conducted globally, and that
explains 30–33% of PCa heritability. The African ancestry has a significant mention in PCa incidence and
presentation. To date, the candidate gene approach has replicated 23 polymorphisms including dinucleotide and
trinucleotide repeats in 16 genes. CYP17-rs743572, CYP3A4-rs2740574, CYP3A5-rs776746, CYP3A43-rs501275, and
haplotype blocks, containing these variants, are significantly associated with PCa among some population groups
but not others. With the few existing studies, the extent of genetic diversity in Africa suggests that genetic
associations of PCa to African ancestry go beyond nucleotide sequence polymorphisms, to a level of environmental
adaptation, which may interpret genetic risk profiles. Also, the shreds of evidence suggest that evolutionary history
contributes to the high rates of PCa relative to African ancestry, and genetic associations do not always replicate
across populations.
Conclusion: The genetic architecture of PCa in Africa provides important contributions to the global understanding
of PCa specifically the African-ancestry hypothesis. There is a need for more prostate cancer consortiums to justify
the heritable certainties of PCa among Africans, and emphasis should be placed on the genetic epidemiological
model of PCa in Africa.
Keywords: Genetic variants, Risk alleles, Prostate cancer
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
* Correspondence: emmanuelachea1990@yahoo.com
1Department of Molecular Medicine, College of Health Sciences, School of
Medical Science, Kwame Nkrumah University of Science and Technology
(KNUST), Kumasi, Ghana
2School of Medical and Health Science, Edith Cowan University, Joondalup,
Australia
Full list of author information is available at the end of the article
Egyptian Journal of Medical
Human Genetics
Acheampong et al. Egyptian Journal of Medical Human Genetics           (2021) 22:33 
https://doi.org/10.1186/s43042-021-00157-w
Background
Prostate cancer (PCa) is the fifth leading cause of death
from cancer in men, with an estimated 307,000 deaths
representing 6.6% of total male cancer mortality [1].
Among men of African descent, PCa is the leading can-
cer in terms of incidence and mortality with approxi-
mately 22.0 per 100,000 population of men affected [2].
There is a consensus that 56% of new cases of cancers
are reported in Africa and other low-middle-income
countries which are projected to reach about 70% by
2030 [3–5]. Regional reports indicate that the age-
adjusted incidence per 100,000 population ranges from
10.6 in Northern Africa to 61.7% in Southern Africa [6].
In sub-Saharan Africa (SSA) alone, disability-adjusted
life years (DALYs) and mortality from prostate cancer
increased from 100,200 to 219,700 and 5600 to 12,300,
respectively over a decade (1990–2010) [7, 8]. Until
recently, major unexplained differences exist in PCa
incidence and mortality between countries in Africa,
subjected to socioeconomic factors and genetics. For ex-
ample, the age-standardized PCa incidence rate per 100,
000 is 37.1 in Uganda [9], 30.5 in Benin [10], 30.26 in
Eritrea [11], 24.5 in Mozambique [12], 20.4 in Northern
Uganda [13], 16.5 in Mauritius [14], and 4.3 in Eastern
Morocco [15]. Aside from these African continent-
specific differences, there are also significant geograph-
ical differences largely due to the underlying biology of
prostate carcinogenesis, the variation in access to screen-
ing and treatment, and exposure to risk factors of PCa
[6]. However, the proportion of racial, ethnic, or
geographical differences in PCa incidence that can be
explained by these factors is relative and poorly
understood.
PCa has one of the highest heritability of all major
cancers [16–19], where the genetic contribution to PCa
risk has been documented and knowledge about the mo-
lecular genetics of the disease is increasing and evolving.
For instance, family based linkage studies have identified
both common and ethnic-specific loci that partly explain
the diversity in PCa incidence. Linkage signals including
12q24, 1q24-25, and 8q24 are common to both
European and non-European descendants and have been
widely replicated in candidate gene studies across diverse
ethnic groups [20]. Also, as of 2014, genome-wide asso-
ciation studies (GWAS) have identified 76 susceptibility
loci associated with PCa risk, and approximately 30% of
the familial risk is due to such variants [21]. This typifies
that understanding the genetic risks of PCa is essential
to personalized medicine and a bridge in understanding
differences in incidence and mortality outcomes.
In this study, we review topics covered on the genetics
of PCa in Africa from January 1990 to September 2020
with detailed sections on (1) inheritance and African-
associated risk, (2) GWAS, and (3) candidate gene
studies in PCa. The review also highlighted the gaps in
knowledge and prospects in the field to translate the
clinical utility of these genetic variants, hitherto un-
decided. Our literature search included Google Scholar,
PubMed, Web of Science, and Scopus. Medical Subject
Heading (MeSH) Terms of PCa (Prostatic Neoplasms)
were tagged to all countries in Africa across the online
databases.
Inheritance and African-associated PCa risk
In 2015, a study among first-degree relatives in Senegal
revealed that being black and having a first-degree rela-
tive with PCa does not appear to increase the risk of
PCa [22]. While this finding remains to be confirmed or
refuted among other African populations, several studies
[23–26] among men with African heritage have reported
a strong familial aggregation of PCa. Unfortunately,
comprehensive meta-analyses conducted thus far, which
provide evidence of familial aggregation of PCa, did not
include any study from Africa. Thus, there are unclear
answers to what aspects of genetic risk contribute to
PCa incidence in Africa. Accordingly, familial studies are
needed to evaluate the true estimate of PCa heritability
in Africa.
Petersen et al. [27] reported a stronger link between
KhoeSan ancestry (in South Africa) and high-risk of
PCa, which can explain a 2-fold increase in PCa presen-
tation in Black South Africans compared with African
Americans (AA). Typical of this finding, the genetic con-
tribution to the burden of PCa among AA has been
traced to West/West-Central Africa that shares about
82% of their ancestral genes [27, 28]. To hold this fact, it
means that modern men of African ancestry are not un-
likely to have undergone selective pressure and possess
PCa risk signatures in their genome with possible famil-
ial aggregation. Accordingly, these signatures may be
conserved in men of African ancestry including the AA,
which may clarify the unexplained 57% PCa heritability
among such populations [19]. Comprehensive studies on
familial aggregation of PCa among Africans, especially
men from West/Western-central Africa, are needed to
understand population risk and extract evidence for per-
sonalized preventive strategies.
Risk alleles at 8q24 region in the African population
Various models have been employed to uncover the
landscape of genetic variations associated with PCa. In
Africa, the GWAS and candidate gene association ap-
proach are the most used models. Genetic variants of
moderate-to-low-risk rather than rare variants with high
penetrance have been widely investigated across Africa,
especially the African MadCap Network. The first study
that tested the transferability of European and AA com-
mon shared variants [20] in the West-African population
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(Nigeria and Cameroon) observed that SNPs rs6983561,
rs7008482, and rs16901979 were significantly associated
with PCa risk [29]. At the same time, they reported that
SNPs rs6983267, rs7008482, and rs7000448 which have
low penetrance (2–4%) in the European population were
prevalent in more than 84% of the West African popula-
tion. Similarly, a prior study by Haiman et al. [30] reported
that the risk allele at the strongest SNP-rs16901979 asso-
ciated with PCa revealed higher penetrance in West
Africans (54%) than European Americans (3%).
Han et al. [31] conducted a fine mapping of the 8q24
PCa-risk region (127.8–128.8Mb) to search for novel
associations with common and rare variations among
men of African Ancestry. Three ancestry-specific signals
(rs72725879, rs114798100, and rs111906932), one of
which is novel (rs111906932) located within or near
some PCa-associated long noncoding RNAs (lncRNAs),
including PRNCR1, PCAT1, and PCAT2, were identified.
These associations were replicated in Ghanaian and
Ugandan men [31]. Also, a comprehensive resequencing
analysis of 250kb region of 8q24.21 in Ghanaian men
replicated similar findings [32]. Similarly, 8q24 risk region
marked by ancestry-specific risk variant rs72725854, near
lncRNAs of PCAT1, accounted for 12% of PCa risk in the
Ugandan population [33]. Moreover, regions marked by
rs7008482 and rs6983267 were replicated in the Black
South African mixed population [34]. The report of
Chung et al. [32] indicated that all 8 PCa-associated loci
and rs13252298 in 8q24 are monomorphic in the
Ghanaian population. This represents that both ancestry-
specific rare and common variants, as well as commonly
shared variants, are present in the African population. For
all the studies, West African men have a much higher
prevalence of 8q24-risk alleles than other populations of
European and Asian ancestry which may explain the
African-ancestry risk burden of PCa among AA
population.
The overall findings suggest that rarer genetic vari-
ation in the 8q24 region may contribute, in part, to the
greater risk of PCa among the African population.
Ahmadiyeh et al. [35] demonstrated that several inde-
pendent polymorphic variants on chromosome 8q24
may produce a conventional biological mechanism that
promotes the disease or regulation of nearby genes (cis-
regulation) or genes on other chromosomes (trans-regu-
lation). Pomerantz et al. [36] also indicated that the
8q24 locus harbors previously unannotated microRNAs
(miRNAs) which are involved in cis-regulation of distal
genes and affecting RNA expression.
The significance of 8q24-risk alleles has been demon-
strated in a recent study among the Ugandan population
[33]. Polygenic risk score including 8q24-risk alleles has
2-times predictive ability than score constructed without
8q24-risk alleles [33], suggesting that variation in this
region may prove vital for risk classification among the
African population. Common variants including
rs7008482, rs72725879, and rs114798100 were transfer-
able in more than one population group in Africa
(Table 1). However, rs6983561 and rs16901979 were
replicated in some population group in Africa but not
others (Table 1), although there were relatively high al-
lele frequencies in such populations. This finding also
suggest that population structure and context-specific
factors influence the definition of risk alleles for a popu-
lation group.
Other risk variants from genome-wide association studies
In GWAS [37, 38], 30 variants were identified to be as-
sociated with PCa in a prostate cancer study in a Ghan-
aian population. However, the most promising
association was the 10p14 locus marked by introns of
noncoding RNAs (rs7918885; 358kb 5′ of GATA3,
RP11-543F8), which depicts evidence of transferability in
the AA population. Subgroup analysis revealed variants
at 5q31 (lead SNP PCDHA1-rs34575154), 22q13.31
(CELSR1-rs6008813), 7q31.31 (rs12537079; 61kb 5′ of
AC003084.2; 119kb 5′ of NAA38), and 2q14.2
(rs12477565; AC012363.13; 22kb 5′ of INHBB), associ-
ated with GS≥7 cancers. SNPs at Xq28 (rs985081; 22kb
3′ of IDS) and 6q21 (rs2185710; 84kb 3′ of U6) were as-
sociated with low GS <7 cancers.
In a genome-wide association meta-analysis among
men of African ancestry, 13q34 candidate signals located
5′ of the gene IRS2 and 3′ of a long noncoding RNA
(rs75823044) and 22q12.1 candidate functional allele in
the CHEK2 gene were novel signals found only in men
of African ancestry [39]. Additionally, according to Fer-
nandez et al. [34], rs10993994 (10q11) showed evidence
of transferability in South-African mixed ancestry men.
A study by Petersen et al. [27] among the South African
Black population identified loci at 2p11.2, 3p14, 8q23,
and 22q13.2 associated with the aggressive presentation
of PCa. In a further comparative analysis using Fisher’s
exact significance test with Bonferroni correction,
22q13.2 and 2p11.2 were associated with Gleason score
(GS) >8. Also, 2p11.2 was associated with PSA ≥ 20 ng/
ml, whereas 8q23 and 3p14 were found to be associated
with PSA-High-risk prostate cancer. Haplotype and
single-marker association analysis identified rs10103786
and rs4504665 within 8q23 that remained significant
after correcting for multiple testing [27]. The loci
enriched with GS ≥ 8 and PSA ≥ 20 ng/ml, 22q13.2 and
2p11.2, have shown evidence of transferability among
different population groups [40–43]. The pattern of PCa
risk allele identification from GWAS is typical of a re-
cent report by the MadCap Network that there are sig-
nificant individual and population-level differences in
PCa risk within the Africa population [44]. Among men
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of African ancestry, Haiman et al. [45] identified novel
risk variants on 17q21 (rs7210100; odds ratio per allele=
1.51; p=3.4×10−13), which has approximately 5% pene-
trance among AA compared with 1% in the white race.
These findings emphasized the significance of GWAS
for discovering significant PCa rare variants associated
with the African race [45].
Candidate gene studies
From January 1990 to September 2020, only 23 poly-
morphisms, including dinucleotide and trinucleotide re-
peats, in 16 genes, have been investigated in association
with PCa in Africa. The cytochrome variants involved in
androgen and estrogen metabolism [46–52] and variants
involved in cell proliferation and inflammation (COX-2
and GSTS genes) [53–56] have been investigated in
multiple studies. CYP17-rs743572, CYP3A4-rs2740574,
CYP3A5-rs776746, CYP3A43-rs501275, and haplotype
blocks containing these variants were significantly asso-
ciated with PCa among Tunisians and the South African
population [46, 47, 49]. However, the association of
CYP3A4-rs2740574 and CYP3A5-rs776746 with PCa was
not replicated among Senegalese men [49]. COX-2 poly-
morphisms (rs3918304 and rs20415) [53] and rs2745557
[54] were transferable to South African and Egyptian
populations, respectively. Whereas polymorphisms in
GSTM1 but not GSTT1 were associated with PCa in the
Tunisian population [55], the association was recipro-
cated in the Algerian population [56]. Other markers in-
volved in nucleotide excision repair (XPC gene) [57],
regulation of cell-cycle progression (ELAC2 gene) [58],
and regulation of androgen receptor (HSP70 and AR
genes) [59, 60], and COMT [52], studied in single stud-
ies, were found to be significantly associated with PCa
risk and severity.
Genetic epidemiological layout of PCa in Africa
Taking together the shreds of evidence from GWAS and
candidate gene association studies, the genetic epidemio-
logical layout of PCa among the African population is
shown in Fig. 1. It appears that the genetic risk of PCa is
more complex and results from polygenic inheritance.
Table 1 Common and rare variants associated with PCa among African population (January 1990–September 2020)
Color representation: green label, ancestry specific signals; blue, commonly shared variance; ash, variants are transferable in some population group but
not others
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The focus of research, thus far, has been on African-
ancestry risk rather than familial aggregation to identify
rare variants with larger effect sizes. The 8q24 locus has
the highest number of independently associated com-
mon and ancestry-specific variants, which might be clin-
ically relevant. Du et al. [41] have demonstrated that
chromatin conformation of 8q24 SNPs exerts long-range
tissue-specific control on MYC expression which gives
potential insight into the pathogenesis of prostate can-
cer. Du et al. [33] further attempted to use risk variants
at 8q24 for risk profiling and exhibited that variation in
this region may prove vital for risk classification among
the African population. It thus, highlights that popula-
tion genetic risk score distribution at this region could
potentially differentiate PCa risks for men more accur-
ately according to their risk score percentile. For ex-
ample, Ugandan men within the 90–99% of genetic risk
scores constructed with 8q24-risk alleles were 4 times
more at risk of PCa.
Additionally, other chromosomal aberrations at 2p11,
3p14, 8q23, 13q34, 5q31, 7q31, and 22q13 are associated
with the aggressive presentation of PCa among the West
African population. Evidence from genetic association
studies also affirms the genetic contribution to PCa
among Africans. Generally, variations in androgen and
estrogen metabolism genes, cell proliferation genes, and
genes involved in inflammation have a high effect on
PCa susceptibility (Table 2). The extent of genetic diver-
sity in Africa and the association pattern to PCa suggest
that genetic and environmental exposure concurrently
interpret genetic risk profiles. Unfortunately, there is
limited data in Africa to support any hypothesis in this
regard. The heterogeneity in risk allele frequencies, non-
replication of risk variant, represents that diverse popu-
lations with African ancestry might share some common
prostate cancer susceptibility alleles that may be differ-
ent from the non-African populations.
Knowledge gaps, prospects, and clinical
implications
The focus of research on the genetics of PCa in Africa
has been the African-ancestry risk hypothesis. Therefore,
available data [37, 38] provides evidence of the high-risk
profile of AA from African-ancestry with unresolved is-
sues of being black and having a first-degree relative
with PCa not associated with increased PCa risk [22].
Fig. 1 Supposed genetic epidemiological of PCa among the African population. The blue boxes indicate that replication studies in a wider
population group of Africans are needed to confirm their clinical and epidemiological usefulness. The green boxes also indicate the variants are
beneficial for population-level profiling to uncover both global cosmopolitan and ancestry-specific signals. Moreover, the orange boxes indicate
that comprehensive studies are warranted to understand the contribution of genetic to PCa inheritance
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There was no evidence of pedigree or affected-sibling pair
studies to understand the genetic contribution of PCa her-
itability in Africa. The impact of this is that most of the
GWAS Consortium are largely focused on potential an-
cestors of AA, excluding largely the Northern, Middle,
and other parts of African countries unexplored [61, 62].
There are significant individual and population-level
differences in prostate cancer risk such that the inclu-
sion of a new set of the population will result in a new
ancestry-specific signal [44]. Currently, the GWAS ap-
proach identified common, low-penetrance, and shared
PCa predisposing variants among the African popula-
tion. These common SNPs have high penetrance (MAF
of at least 5%) with modest effect sizes and explain about
12% of the genetic contribution to PCa risk [33], leaving
the majority of risk unexplained. The rare variant hy-
pothesis [63] may be substantial in this regard, which
necessitates the need to go beyond the commonly used
SNP arrays in GWAS. Accordingly, high-coverage tar-
geted or whole-genome sequencing in a larger sample
will provide sufficient statistical power to allow a direct
variant-by-variant analysis [64].
Table 2 Variants from candidate gene association studies associated with PCa among Africans (January 1990–September 2020)
Color representation: ash, variants are transferable in some population group but not others
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Current efforts in the genetics of PCa have a goal to-
wards personalized therapy for patients. Thus, important
genetic epidemiological and functional studies are
needed to understand the role of these variants. How-
ever, there is no consensus on the genetic architecture
of Africans. In terms of individual risk profiling, the
functional aspects of these variants are needed for tar-
geted treatment programs. Thus, a wide range of genetic
consortia is needed to interrogate the genomes of the
African population by pooling efforts and resources.
Conclusion
The genetic architecture of PCa in Africa provides im-
portant contributions to the global understanding of
PCa specifically the African-ancestry hypothesis. Al-
though African ancestry has been successfully used to
fine-mapped important variants, it only explains 30–33%
of prostate cancer heritability. However, to what extent
and aspects to which genetic variants explain PCa herit-
ability in Africa are limited. Therefore, more prostate
cancer consortiums are needed to justify the heritable
certainties of PCa among Africans, and emphasis should
be placed on the genetic epidemiological model of PCa
in Africa. What we can appreciate is that the use of
comprehensive methods in the search for genetic vari-
ants and functions have highlighted important candidate
genes that perform a special function in PCa biology.
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